Whitepaper

Adoption of Innovative Technologies within Pharmaceutical R&D | AI in Pharma R&D

100% of biopharma companies surveyed rate pilots and POCs as important to adopting new technologies.

This is just one of the key findings in a new study conducted by the Tufts Center for the Study of Drug Development, designed to help the industry catch up to other vertical markets in terms of digital maturity, such as the adoption of AI in pharma R&D.

In this whitepaper, you’ll gain insights for overcoming barriers that prevent AI and other innovative technologies from improving operational efficiency, performance, and cost reduction across your entire value chain.

  • Download Whitepaper

  • You may unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.